← Leaderboards
Laith Al-Rabadi
University Of Utah
$526,380
Attributed
$526,380
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $176.5K · FY2023–25$200K$150K$100K$50K$0
'23
'24
'25
Funding mix
By agency
NIH$526,380 · 1
By mechanism
K23$526,380 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Utah
Same institution · by research overlap
- David J Stillman$11,832,241
- Susan E Mango$9,061,235
- Bradley R Cairns$10,773,002
- Carl S. Thummel$15,049,537
- Richard I Dorsky$6,853,000
Others in their field
Other Rising Stars on “Animal Model”
- Mari Ostendorf · University Of Washington$51,931,230
- Dorota A. Grejner-Brzezinska · University Of Wisconsin-Madison$19,883,568
- Kevin Saunders · Duke University$18,106,404
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
- Maximilian Haeussler · University Of California Santa Cruz$12,592,563
Research focus
Animal ModelAnimalsAntibodiesAntibody Titer MeasurementAntigen-Antibody ComplexAntigensAntigen TargetingAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmune ProcessAutoimmune ResponsesAutomobile DrivingAwardBasement MembraneBindingBloodBrainBruch&AposCareer ChoiceCareer DevelopmentChromatin ImmunoprecipitationCirculationAlbuminuria
Grant awards (3)
The Serine Protease HTRA1 Antigen: A Gateway to Elucidating Membranous Nephropathy Pathogenesis and the Targeting of Antigen Epitopes$174,960
K23 · FY2025 · DK · contact PI
The Serine Protease HTRA1 Antigen: A Gateway to Elucidating Membranous Nephropathy Pathogenesis and the Targeting of Antigen Epitopes$174,960
K23 · FY2024 · DK · contact PI
The Serine Protease HTRA1 Antigen: A Gateway to Elucidating Membranous Nephropathy Pathogenesis and the Targeting of Antigen Epitopes$176,460
K23 · FY2023 · DK · contact PI